Thc Therapeutics Stock Analysis
| THCT Stock | USD 0.01 0.01 8,500% |
THC Therapeutics has over 925,890 in debt which may indicate that it relies heavily on debt financing. THC Therapeutics' financial risk is the risk to THC Therapeutics stockholders that is caused by an increase in debt.
Asset vs Debt
Equity vs Debt
THC Therapeutics' liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. THC Therapeutics' cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the Company is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps THC Pink Sheet's retail investors understand whether an upcoming fall or rise in the market will negatively affect THC Therapeutics' stakeholders.
For many companies, including THC Therapeutics, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for THC Therapeutics, the most critical issue when managing liquidity is ensuring that current assets are properly aligned with current liabilities. If they are not, THC Therapeutics' management will need to obtain alternative financing to ensure there are always enough cash equivalents on the balance sheet to meet obligations.
Given that THC Therapeutics' debt-to-equity ratio measures a Company's obligations relative to the value of its net assets, it is usually used by traders to estimate the extent to which THC Therapeutics is acquiring new debt as a mechanism of leveraging its assets. A high debt-to-equity ratio is generally associated with increased risk, implying that it has been aggressive in financing its growth with debt. Another way to look at debt-to-equity ratios is to compare the overall debt load of THC Therapeutics to its assets or equity, showing how much of the company assets belong to shareholders vs. creditors. If shareholders own more assets, THC Therapeutics is said to be less leveraged. If creditors hold a majority of THC Therapeutics' assets, the Company is said to be highly leveraged.
THC Therapeutics is undervalued with Real Value of 0.009425 and Hype Value of 0.01. The main objective of THC Therapeutics pink sheet analysis is to determine its intrinsic value, which is an estimate of what THC Therapeutics is worth, separate from its market price. There are two main types of THC Therapeutics' stock analysis: fundamental analysis and technical analysis.
The THC Therapeutics pink sheet is traded in the USA on PINK Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA.
THC |
THC Pink Sheet Analysis Notes
About 31.0% of the company outstanding shares are owned by corporate insiders. The company recorded a loss per share of 0.09. THC Therapeutics last dividend was issued on the 10th of December 2018. The entity had 1:10 split on the 10th of December 2018. It is involved in the development of dHydronator, a sanitizing herb dryer for drying and sanitizing of freshly harvested cannabis, other herbs, flowers, and tea leaves. THC Therapeutics, Inc. was incorporated in 2007 and is based in Las Vegas, Nevada. Thc Therapeutics operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. It employs 1 people.The quote for THC Therapeutics is published daily by the National Quotation Bureau and the company does not need to meet minimum requirements or file with the SEC. To find out more about THC Therapeutics contact Brandon Romanek at 833 420 8428 or learn more at https://thct.io.THC Therapeutics Investment Alerts
| THC Therapeutics is way too risky over 90 days horizon | |
| THC Therapeutics has some characteristics of a very speculative penny stock | |
| THC Therapeutics appears to be risky and price may revert if volatility continues | |
| THC Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| THC Therapeutics currently holds 925.89 K in liabilities with Debt to Equity (D/E) ratio of 18.7, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. THC Therapeutics has a current ratio of 0.01, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist THC Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, THC Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like THC Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for THC to invest in growth at high rates of return. When we think about THC Therapeutics' use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (1.89 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| THC Therapeutics currently holds about 3.82 K in cash with (388.48 K) of positive cash flow from operations. | |
| Roughly 31.0% of THC Therapeutics outstanding shares are owned by corporate insiders |
THC Market Capitalization
The company currently falls under 'Nano-Cap' category with a current market capitalization of 1.09 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate THC Therapeutics's market, we take the total number of its shares issued and multiply it by THC Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.Technical Drivers
As of the 13th of February 2026, THC Therapeutics owns the risk adjusted performance of 0.1507, and Standard Deviation of 1184.78. Compared to fundamental indicators, the technical analysis model makes it possible for you to check helpful technical drivers of THC Therapeutics, as well as the relationship between them.THC Therapeutics Price Movement Analysis
Illegal number of arguments. The output start index for this execution was zero with a total number of output elements of zero. The Weighted Moving Average calculates a weight for each value in THC Therapeutics price series with the more recent values given greater weights.
THC Therapeutics Outstanding Bonds
THC Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. THC Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most THC bonds can be classified according to their maturity, which is the date when THC Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
THC Therapeutics Predictive Daily Indicators
THC Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of THC Therapeutics pink sheet daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Daily Balance Of Power | 9.2 T | |||
| Rate Of Daily Change | 86.0 | |||
| Day Median Price | 0.0086 | |||
| Day Typical Price | 0.0086 | |||
| Price Action Indicator | 0.0043 | |||
| Period Momentum Indicator | 0.0085 |
THC Therapeutics Forecast Models
THC Therapeutics' time-series forecasting models are one of many THC Therapeutics' pink sheet analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary THC Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.THC Therapeutics Debt to Cash Allocation
THC Therapeutics currently holds 925.89 K in liabilities with Debt to Equity (D/E) ratio of 18.7, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. THC Therapeutics has a current ratio of 0.01, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist THC Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, THC Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like THC Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for THC to invest in growth at high rates of return. When we think about THC Therapeutics' use of debt, we should always consider it together with cash and equity.THC Therapeutics Assets Financed by Debt
Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the THC Therapeutics' operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of THC Therapeutics, which in turn will lower the firm's financial flexibility.THC Therapeutics Corporate Bonds Issued
About THC Pink Sheet Analysis
Pink Sheet analysis is the technique used by a trader or investor to examine and evaluate how THC Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling THC shares will generate the highest return on investment. We also built our pink sheet analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Pink Sheet such as THC Therapeutics. By using and applying THC Pink Sheet analysis, traders can create a robust methodology for identifying THC entry and exit points for their positions.
It is involved in the development of dHydronator, a sanitizing herb dryer for drying and sanitizing of freshly harvested cannabis, other herbs, flowers, and tea leaves. THC Therapeutics, Inc. was incorporated in 2007 and is based in Las Vegas, Nevada. Thc Therapeutics operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. It employs 1 people.
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our pink sheet analysis tools, you can find out how much better you can do when adding THC Therapeutics to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Top Crypto Exchanges Now
Top Crypto ExchangesSearch and analyze digital assets across top global cryptocurrency exchanges |
| All Next | Launch Module |
Additional Tools for THC Pink Sheet Analysis
When running THC Therapeutics' price analysis, check to measure THC Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy THC Therapeutics is operating at the current time. Most of THC Therapeutics' value examination focuses on studying past and present price action to predict the probability of THC Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move THC Therapeutics' price. Additionally, you may evaluate how the addition of THC Therapeutics to your portfolios can decrease your overall portfolio volatility.